Drug intelligence / Profile preview

TBC-FPV

Development stage: Unknown
Lead developer: Bavarian Nordic

Overview

The term "TBC-FPV" is not a recognized drug name in public databases. The abbreviation "FPV" is highly ambiguous and can refer to several distinct entities. Among pharmaceutical drugs, "FPV" commonly refers to either Favipiravir or Fosamprenavir. Favipiravir is an antiviral drug primarily used for influenza and repurposed for COVID-19, acting as a nucleoside-based inhibitor of viral RNA-dependent RNA polymerase through lethal mutagenesis. Fosamprenavir is an antiretroviral prodrug used in the treatment of HIV/AIDS, which is metabolized in the body to its active form, amprenavir, an HIV protease inhibitor.

Beyond the preview

Go deeper on TBC-FPV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC-FPV.

Explore the full profile